P53 nuclear stabilization is associated with FHIT loss and younger age of onset in squamous cell carcinoma of oral tongue

BMC Clinical Pathology

Murali Dharan Bashyam¹  Mohana Vamsy Chigurupati³  Snehalatha Dhagam³  Umanath K Nayak⁴  Shantveer G Uppin⁷  Subramanyeshwar Rao²  Mohammed Mujtaba Ali⁶  Mukta Srinivasulu⁶  Swarnalata Gowrishankar⁴  Neha A Gupta⁵  Viswakalyan Kotapalli¹  Raju SR Adduri¹ 

[1] Laboratory of Molecular Oncology, Centre for DNA Fingerprinting and Diagnostics, Nampally, Hyderabad 500001, India;Currently at Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, India;Omega Hospitals, Jubilee Hills, Hyderabad, India;Apollo Hospitals, Jubilee Hills, Hyderabad India;Currently at National Centre for Cell Science, Ganeshkhind, Pune, India;MNJ Institute of Oncology & Regional Cancer Centre, Red Hills, Hyderabad India;Nizam’s Institute of Medical Sciences, Punjagutta, Hyderabad India

关键词: Disease specific survival;    EGFR;    FHIT;    TP53;    Oral tongue cancer;   

Others  :  1084512
DOI  :  10.1186/1472-6890-14-37

 received in 2014-06-13, accepted in 2014-07-29,  发布年份 2014

【 摘 要 】

Background

Squamous cell carcinoma of tongue (SCCT) is expected to harbor unique clinico-pathological and molecular genetic features since a significant proportion of patients are young and exhibit no association with tobacco or alcohol.

Methods

We determined P53, epidermal growth factor receptor, microsatellite instability, human papilloma virus infection and loss of heterozygosity status at several tumor suppressor loci in one hundred and twenty one oral SCCT (SSCOT) samples and analyzed their association with clinico-pathological features and patient survival.

Results

Our results revealed a significantly higher incidence of p53 nuclear stabilization in early (as against late) onset SCCOT. FHIT loss was significantly associated with p53 nuclear stabilization and the association was stronger in patients with no history of tobacco use. Samples harboring mutation in p53 DNA binding domain or exhibiting p53 nuclear stabilization, were significantly associated with poor survival.

Conclusion

Our study has therefore identified distinct features in SCCOT tumorigenesis with respect to age and tobacco exposure and revealed possible prognostic utility of p53.

【 授权许可】

   
2014 Adduri et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Myers JN, Elkins T, Roberts D, Byers RM: Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes. Otolaryngol Head Neck Surg 2000, 122:44-51.
• [2]Dahlstrom KR, Little JA, Zafereo ME, Lung M, Wei Q, Sturgis EM: Squamous cell carcinoma of the head and neck in never smoker-never drinkers: a descriptive epidemiologic study. Head Neck 2008, 30:75-84.
• [3]Iype EM, Pandey M, Mathew A, Thomas G, Sebastian P, Nair MK: Oral cancer among patients under the age of 35 years. J Postgrad Med 2001, 47:171-176.
• [4]Sarkaria JN, Harari PM: Oral tongue cancer in young adults less than 40 years of age: rationale for aggressive therapy. Head Neck 1994, 16:107-111.
• [5]Silverman S Jr: Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc 2001, 132 Suppl(132 Suppl):7S-11S.
• [6]Ryott M, Wangsa D, Heselmeyer-Haddad K, Lindholm J, Elmberger G, Auer G, Avall Lundqvist E, Ried T, Munck-Wikland E: EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma. Eur J Cancer 2009, 45:1700-1708.
• [7]Pandilla Ramaswamy KV, Gowrishankar S, Vamsy CM, Patnaik S, Uppin S, Rao S, Kalidindi N, Regulagadda S, Sundaram C, Srinivasulu M, Vasala A, Bashyam MD: Distinct genetic aberrations in oesophageal adeno and squamous carcinoma. Eur J Clin Invest 2013, 43:1233-1239.
• [8]Raman R, Kotapalli V, Adduri R, Gowrishankar S, Bashyam L, Chaudhary A, Vamsy M, Patnaik S, Srinivasulu M, Sastry R, Rao S, Vasala A, Kalidindi N, Pollack J, Murthy S, Bashyam M: Evidence for possible non-canonical pathway(s) driven early-onset colorectal cancer in India. Mol Carcinog 2014, 53(Suppl 1):E181-6.
• [9]Joerger AC, Fersht AR: Structural biology of the tumor suppressor p53. Annu Rev Biochem 2008, 77:557-582.
• [10]Cho Y, Gorina S, Jeffrey PD, Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994, 265:346-355.
• [11]Kalyankrishna S, Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006, 24:2666-2672.
• [12]Peltonen JK, Helppi HM, Paakko P, Turpeenniemi-Hujanen T, Vahakangas KH: P53 in head and neck cancer: functional consequences and environmental implications of TP53 mutations. Head Neck Oncol 2010, 2:36. BioMed Central Full Text
• [13]Khan Z, Tiwari RP, Mulherkar R, Sah NK, Prasad GB, Shrivastava BR, Bisen PS: Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings. Head Neck 2009, 31:1039-1048.
• [14]Nylander K, Nilsson P, Mehle C, Roos G: p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. Br J Cancer 1995, 71:826-830.
• [15]De Paula AM, Souza LR, Farias LC, Correa GT, Fraga CA, Eleuterio NB, Silveira AC, Santos FB, Haikal DS, Guimaraes AL, Gomez RS: Analysis of 724 cases of primary head and neck squamous cell carcinoma (HNSCC) with a focus on young patients and p53 immunolocalization. Oral Oncol 2009, 45:777-782.
• [16]Feng Z, Hu W, Teresky AK, Hernando E, Cordon-Cardo C, Levine AJ: Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A 2007, 104:16633-16638.
• [17]Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih Ie M, Kurman RJ: Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 2011, 24:1248-1253.
• [18]Sorensen DM, Lewark TM, Haney JL, Meyers AD, Krause G, Franklin WA: Absence of p53 mutations in squamous carcinomas of the tongue in nonsmoking and nondrinking patients younger than 40 years. Arch Otolaryngol Head Neck Surg 1997, 123:503-506.
• [19]Lingen MW, Chang KW, McMurray SJ, Solt DB, Kies MS, Mittal BB, Haines GK, Pelzer HJ: Overexpression of p53 in squamous cell carcinoma of the tongue in young patients with no known risk factors is not associated with mutations in exons 5–9. Head Neck 2000, 22:328-335.
• [20]D’Costa J, Saranath D, Dedhia P, Sanghvi V, Mehta AR: Detection of HPV-16 genome in human oral cancers and potentially malignant lesions from India. Oral Oncol 1998, 34:413-420.
• [21]Marur S, D’Souza G, Westra WH, Forastiere AA: HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010, 11:781-789.
• [22]Wang Y, Irish J, MacMillan C, Brown D, Xuan Y, Boyington C, Gullane P, Kamel-Reid S: High frequency of microsatellite instability in young patients with head-and-neck squamous-cell carcinoma: lack of involvement of the mismatch repair genes hMLH1 AND hMSH2. Int J Cancer 2001, 93:353-360.
• [23]Glavac D, Volavsek M, Potocnik U, Ravnik-Glavac M, Gale N: Low microsatellite instability and high loss of heterozygosity rates indicate dominant role of the suppressor pathway in squamous cell carcinoma of head and neck and loss of heterozygosity of 11q14.3 correlates with tumor grade. Cancer Genet Cytogenet 2003, 146:27-32.
• [24]Koy S, Plaschke J, Luksch H, Friedrich K, Kuhlisch E, Eckelt U, Martinez R: Microsatellite instability and loss of heterozygosity in squamous cell carcinoma of the head and neck. Head Neck 2008, 30:1105-1113.
• [25]Loukola A, Eklin K, Laiho P, Salovaara R, Kristo P, Jarvinen H, Mecklin JP, Launonen V, Aaltonen LA: Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res 2001, 61:4545-4549.
• [26]Partridge M, Emilion G, Pateromichelakis S, Phillips E, Langdon J: Location of candidate tumour suppressor gene loci at chromosomes 3p, 8p and 9p for oral squamous cell carcinomas. Int J Cancer 1999, 83:318-325.
• [27]Saranath D, Tandle AT, Deo MG, Mehta AR, Sanghvi V: Loss of p53 gene as a biomarker of high risk oral leukoplakias. Indian J Biochem Biophys 1997, 34:266-273.
• [28]Croce CM, Sozzi G, Huebner K: Role of FHIT in human cancer. J Clin Oncol 1999, 17:1618-1624.
• [29]Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM, Pierotti MA, Sozzi G: The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A 1999, 96:8489-8492.
• [30]Andriani F, Roz E, Caserini R, Conte D, Pastorino U, Sozzi G, Roz L: Inactivation of both FHIT and p53 cooperate in deregulating proliferation-related pathways in lung cancer. J Thorac Oncol 2012, 7:631-642.
• [31]Lee YC, Wu CT, Shih JY, Jou YS, Chang YL: Frequent allelic deletion at the FHIT locus associated with p53 overexpression in squamous cell carcinoma subtype of Taiwanese non-small-cell lung cancers. Br J Cancer 2004, 90:2378-2383.
• [32]Mannarini L, Bertino G, Morbini P, Villa C, Benazzo M: Markers of chemoradiation resistance in patients with locally advanced head and neck squamous cell carcinoma, treated by intra-arterial carboplatin and concurrent radiation. Acta Otorhinolaryngol Ital 2007, 27:173-180.
• [33]Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, Pilotti S, Licitra L: TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol 2010, 28:761-766.
• [34]Kujan O, Oliver R, Roz L, Sozzi G, Ribeiro N, Woodwards R, Thakker N, Sloan P: Fragile histidine triad expression in oral squamous cell carcinoma and precursor lesions. Clin Can Res 2006, 12:6723-6729.
• [35]Tai SK, Lee JI, Ang KK, El-Naggar AK, Hassan KA, Liu D, Lee JJ, Ren H, Hong WK, Mao L: Loss of FHIT expression in head and neck squamous cell carcinoma and its potential clinical implication. Clin Can Res 2004, 10:5554-5557.